The corporate takeover of Alzheimer's treatment: a crisis in neurological autonomy?

TL;DR

This editorial discusses how corporate influence in Alzheimer's treatment is affecting neurological autonomy and physician-patient relationships.

Contribution

The paper highlights the impact of corporate healthcare dominance on neurological practice and proposes strategies to preserve medical integrity.

Findings

Corporate healthcare organizations are increasingly dominating Alzheimer's treatment supply.

This trend undermines physician autonomy and traditional patient relationships.

Strategies are proposed to maintain neurological therapy integrity in the face of corporate influence.

Abstract

The recent approval of monoclonal antibodies for the treatment of Alzheimer's disease represents a significant advancement in neurology. This accomplishment coincides with a worrisome trend: the increasing hegemony of large corporate healthcare organizations and commercial laboratory corporations in the supply of these new medications. This editorial examines how corporate influence undermines the traditional physician–patient relationship, diminishes neurologist autonomy, and signals a broader incursion into neurological practice by nonspecialists. The current situation in Brazil, compared with the United States and Europe, including the United Kingdom, is discussed, and strategies are proposed to maintain the integrity of neurological therapy amid growing corporate influence in the medical field.